BiotechTube

Half-dose of the Tc99-m sestamibi (Cardiolite)

Pre-clinicalTerminated
0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myocardial Infarction

Conditions

Myocardial Infarction, Ischemic Heart Disease

Trial Timeline

Oct 1, 2011 → Dec 1, 2014

NCT ID
NCT01499654

About Half-dose of the Tc99-m sestamibi (Cardiolite)

Half-dose of the Tc99-m sestamibi (Cardiolite) is a pre-clinical stage product being developed by Astellas Pharma for Myocardial Infarction. The current trial status is terminated. This product is registered under clinical trial identifier NCT01499654. Target conditions include Myocardial Infarction, Ischemic Heart Disease.

What happened to similar drugs?

20 of 20 similar drugs in Myocardial Infarction were approved

Approved (20) Terminated (3) Active (0)
✅AbciximabEli LillyApproved
✅AbciximabEli LillyApproved
✅abciximabEli LillyApproved
✅Ticagrelor + ClopidogrelAstraZenecaApproved
✅ticagrelor + aspirinAstraZenecaApproved
✅Ticagrelor + PlaceboAstraZenecaApproved
✅Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)AstraZenecaApproved

Hype Score Breakdown

Clinical
3
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01499654Pre-clinicalTerminated

Competing Products

20 competing products in Myocardial Infarction

See all competitors
ProductCompanyStageHype Score
Butylphthalide + Butylphthalide placeboCSPC Pharmaceutical Group LimitedPhase 3
47
AbciximabEli LillyApproved
43
Prasugrel + ClopidogrelDaiichi SankyoPhase 3
40
Regadenoson + gadofoveset trisodiumAstellas PharmaPhase 2
35
No interventionAstellas PharmaPre-clinical
22
Empagliflozin + PlaceboEli LillyPhase 3
40
Abciximab + Abciximab placeboEli LillyPhase 3
36
Intracoronary infusion of enriched bone marrow-derived progenitor cells + Placebo medium supplemented with autologous serumEli LillyPhase 3
40
AbciximabEli LillyApproved
43
abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximabEli LillyPhase 3
40
fibrinolytic therapy or combination reduced fibrinolytic therapyEli LillyPhase 3
40
abciximabEli LillyApproved
43
tenecteplase + enoxaparin + clopidogrelEli LillyPhase 2/3
38
Thrombolytic therapyEli LillyPre-clinical
22
TicagrelorAstraZenecaPre-clinical
26
TicagrelorAstraZenecaPhase 2
31
Dual-antiplatelet therapy + Dual-antiplatelet therapyAstraZenecaPre-clinical
22
Metoprolol- Toprol XL + Metoprolol- LopressorAstraZenecaPhase 1
29
Ticagrelor orodispersible tablets + Ticagrelor standard tabletsAstraZenecaPhase 3
40
RosuvastatinAstraZenecaPhase 3
40